Skip to main content

DoseVue NV

DoseVue NV was founded in March 2013, by Emiliano D’Agostino and the Belgian Nuclear ResearchCenter (SCK•CEN). Pursuing optimal use of ionising radiation in clinical practice, its mission is the design and development of advanced in-vivo dosimetry systems. Within this context, Amphora perfectly matches DoseVue’s mission  statement  and  converges  with  its  long-term  vision  on  in vivo  dosimetry  within  the  field  of radiation therapy.

Focusing on in vivo dosimetry applications in healthcare, DoseVue NV has extensive knowledge of  Amphora’s application field. Moreover, referring to the included short resumes of its two FTEs, DoseVue has extensive  expertise  in  patient  dosimetry,  radiation  protection,  and  image  and  signal  processing, including ultrasound.

 

 


Master in Nuclear Engineering

Emiliano D’Agostino

Dr. E. D'Agostino obtained his master in Nuclear Engineering from the Politecnico di Milano, Italy, in 2001. After being selected to participate to the T.I.M.E. (Top Industrial Manager for Europe) program, he spent two years at the Ecole Polytechnique of the Universite Libre de Brussel, where he received a Master in Physics Engineering, also in 2001. In 2001, he started his PhD at the KU Leuven, within the Medical Image Computing laboratory, under the supervision of Professor Paul Suetens, in the field of medical image analysis. He obtained his PhD in 2006. After his PhD graduation, Dr. D'Agostino worked one year as post-doctoral fellow at the Medical Imaging Research Center, KU Leuven, where he was internal coordinator  of  the  research  projects funded  by  the  IBBT  (Instituut  voor  Breed  Band Technologie). In 2007 he left KU  Leuven  and  worked  for  6 months  at  IMEC,  within  the  unit  of Business Development, on a feasibility project of a new technology for medical imaging. In march 2008 he  joined  the  Belgian  Nuclear  Research  Center,  where  he  worked  as  a  research scientist  within  the groups  of Dosimetry and Radiation  Protection  and  of  Radiobiology.  During  his  period  at  the Belgian Nuclear Research Center, his research interests were focused on charged particle therapy (hadrontherapy) and on the development of new instrumentation for measuring  the dose absorbed by  patients  undergoing  radiation therapy.  He  currently  supervises  and/or  co-supervises  5  PhD students.

Dr. D'Agostino has served as reviewer for the major journal in the field on medical imaging, including, Medical Image Analysis, IEEE Transaction on Medical Imaging and Neuroimage. He was also selected, in 2005 and 2007, as expert by the European Commission for the review of project proposals submitted with the FP7-Health program. He was full member of the European Dosimetry Association (EURADOS), where he was part the working group on (radiotherapy) patients dosimetry. Reviewer experience for different major journals in the field of medical imaging.

In March 2013 Dr. D’Agostino founded DoseVue NV, in collaboration with the Belgian Nuclear Research Center. The scope of DoseVue NV is the development of innovative technology for in-vivo dosimetry.


Tasks and Tools

DoseVue NV will mainly focus on following tasks.

Radiation-Sensitive UCA Design: DoseVue NV will closely collaborate with Tor Vergata university and IMEC towards the design and development of radiation sensitive UCAs (WP1). Its knowledge related to  the  response  of different  kinds  of  materials  to  ionising  radiation,  can  be  used  to  assist  the development of dosimetric UCAs.

Ultrasound  Read-Out: DoseVue  NV  will  closely  collaborate  with  KU  Leuven  and  Fraunhofer  IBMT towards design  and  development  of  the  differential  ultrasound  measurement  approach  for dose 
extraction (WP4). Advanced signal processing is one of DoseVue’s core competencies, that will be used to  design  and  develop advanced algorithms  and  tailored  pulse  sequences  for  ultrasound dose  read-out.

Validation: DoseVue  NV  will  contribute  in  the  validation  of  the  new  dosimetry  concept  that  will  be benchmarked against  state  of  the  art  dosimetry  technologies  (WP6).  DoseVue  will  provide  OSL  for reference  dose  measurements, and  will  perform  Monte-Carlo  calculations  to  extend  these  point measurements to dose distributions.

At  the  Belgian  Nuclear  Research Center,  DoseVue  NV  can  make  use of  certified  nuclear  calibration laboratories, in order to benchmark the new developed dosimetric technology, versus the state of the art. Beside several calibrated beams, different kinds of state of the art detectors, as well as simulation tools are present.


AMPHORA aims to develop a non-invasive in-situ dosimetry system for radiation therapy with the potential of on-line dose assessment by casting ultrasound contrast agents (UCAs) into dose sensing theranostic devices.